Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Galectin Therapeutic (GALT)

Galectin Therapeutic (GALT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Galectin Therapeutic 4960 PEACHTREE INDUSTRIAL BLVD. SUITE 240 NORCROSS GA 30071 USA

www.galectintherapeutics.com Employees: 14 P: 678-620-3186 F: 770-864-1327

Description:

Galectin Therapeutics Inc. is a drug development company engaged in the development new therapies for fibrotic disease and cancer. The Company uses its carbohydrate technology that targets galectin proteins, the key mediators of biologic and pathologic function. Galectin Therapeutics uses naturally occurring carbohydrate polymers with galactose residues to create complex carbohydrates with specific molecular weights. Galectin Therapeutics, formerly known as Pro-Pharmaceuticals, Inc. is headquartered in Newton, Massachusetts.

Key Statistics

Overview:

Market Capitalization, $K 65,272
Enterprise Value, $K 41,832
Shares Outstanding, K 62,762
Annual Sales, $ 0 K
Annual Net Income, $ -41,070 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -11,220 K
EBIT, $ -39,570 K
EBITDA, $ -39,540 K
60-Month Beta 0.69
% of Insider Shareholders 50.10%
% of Institutional Shareholders 11.68%
Float, K 31,318
% Float 49.90%
Short Volume Ratio 0.23

Growth:

1-Year Return -39.18%
3-Year Return -56.12%
5-Year Return -63.89%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth -94.74%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.18 on 11/14/24
Next Earnings Date 11/18/24
Earnings Per Share ttm -0.73
EPS Growth vs. Prev Qtr 10.00%
EPS Growth vs. Prev Year 25.00%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-6 on 03/23/12

GALT Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 0.00%
Return-on-Assets % -163.15%
Profit Margin % 0.00%
Debt/Equity 0.00
Price/Sales N/A
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share -1.48
Interest Coverage -13.72
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar